For years, people who use CBD have had to purchase it out-of-pocket. But new federal policy developments suggest that may soon begin to change.

A pilot program being developed through the Centers for Medicare & Medicaid Services (CMS) may allow certain Medicare patients to access up to $500 per year in qualifying hemp-derived CBD products through participating healthcare providers.

If implemented as planned, this would represent one of the first times federal healthcare programs explore covering hemp-derived cannabinoid products.

Here’s what we currently know.

What Is the New Medicare CBD Pilot Program?

The federal government has announced a pilot program designed to explore how hemp-derived cannabinoid products might be integrated into healthcare settings.

Under the program:

Eligible Medicare patients could receive up to $500 annually toward qualifying CBD products
Products must be derived from federally legal hemp
CBD may need to be recommended by a participating physician or healthcare provider
The program will be tested through CMS Innovation Center healthcare models

The initiative is expected to begin as early as April 2026 in selected healthcare systems.

Why the Government Is Exploring CBD Coverage

Federal health agencies say the goal of the pilot program is to collect real-world data about how cannabinoid products are used by patients.

Researchers want to better understand how CBD may fit into wellness routines for older adults and individuals managing common health challenges.

The program may also help policymakers determine whether hemp-derived cannabinoid products should play a larger role in future healthcare programs.

What CBD Products Might Qualify?

Only certain products are expected to qualify under the program.

Based on current guidance, eligible products would likely need to meet several requirements:

• Derived from federally legal hemp

• Contain less than 0.3% delta-9 THC

• Be produced according to federal and state safety standards

• Be provided through participating healthcare providers

Products would also need to comply with state and local laws, which may vary across the United States.

Can CBD Be Written Off as a Medical Expense?

Another question people often ask is whether CBD can be deducted on taxes.

In some cases, health-related purchases may qualify as medical expenses if they are:

• recommended by a licensed healthcare provider

• used for a specific health purpose

• properly documented

However, tax rules can vary widely depending on individual circumstances. Anyone considering this option should consult a qualified tax professional to determine eligibility.

Why This Could Be a Major Shift for CBD

CBD has grown rapidly in popularity over the past decade. Surveys suggest millions of Americans use hemp-derived products as part of their daily wellness routines.

However, healthcare coverage has historically been limited because most CBD products are not approved as prescription medications.

Programs like this pilot could help federal agencies:

• collect real-world data

• evaluate safety and product quality

• understand how cannabinoid products are used by patients

If successful, similar programs could potentially expand in the future.

What This Means for CBD Consumers

While the program is still evolving, a few key things are clear:

• Medicare CBD coverage is not universal yet

• the program will likely begin as a limited pilot

• physician involvement may be required

• qualifying products must meet federal hemp rules

More guidance from CMS and healthcare providers is expected as the program develops.

The Bottom Line

CBD products have traditionally been something consumers purchase on their own. But emerging federal policies suggest that healthcare systems are beginning to explore how hemp-derived cannabinoids might fit into patient wellness programs.

If the Medicare pilot program moves forward as planned, eligible patients could receive up to $500 per year in coverage for qualifying hemp-derived CBD products, marking a potentially important moment for the future of cannabinoid policy in the United States.